

AGENDA ITEM BRIEFING

Submitted by: Gregory R. Anderson, Chief Financial Officer and Treasurer

Subject: Approval to Amend the FY 2013-FY 2017 Texas A&M University System Capital Plan to Add the Pandemic Influenza Facility Project (Project No. 1-3150) for The Texas A&M University System with a Fiscal Year 2013 Start Date

Proposed Board Action:

- (1) Amend the approved FY 2013-FY 2017 Texas A&M University System Capital Plan to add the Pandemic Influenza Facility Project for The Texas A&M University System with an FY 2013 start date and a total planning amount of \$78,431,373.
- (2) Appropriate \$7,500,000 for pre-construction services and related project costs, subject to finalization of state funding for the Center for Innovation in Advanced Development & Manufacturing (CIADM).

Funding/Planning Amount:

<u>Funding Source</u>	<u>Planning Amount</u>	<u>Average Estimated Annual Debt Service</u>	<u>Debt Service Source</u>
Federal Grant	\$38,431,373	N/A	N/A
State Funds	<u>\$40,000,000</u>	N/A	N/A
Total Project Funds	<u>\$78,431,373</u>		

Project Justification:

As part of the U.S. Department of Health and Human Services (DHHS) CIADM, The Texas A&M University System proposes to construct a new Pandemic Influenza Facility (PIF). The PIF will fulfill a contract requirement to provide U.S.-based biopharmaceutical production surge capacity for pandemic influenza vaccine and other threats. When not producing pandemic vaccine, GlaxoSmithKline will utilize the PIF to produce seasonal influenza vaccine to support clinical trials and an eventual Biologics Licensing Application (BLA), which is currently supported by a separate development contract from BARDA (Health and Human Services Contract O100200600011C). The PIF will be a key component of the desired strategic national capability to rapidly develop, license and manufacture a variety of vaccines and therapeutic products critical for biosecurity and global health.

Agenda Item No. 7
Agenda Item Briefing

Scope:

The project will be located south of the Health Science Center campus in the new designated bio-corridor area of Bryan/College Station.

The new facility will include:

- + Modular clean rooms for vaccine manufacturing processes
- + Quality control laboratories
- + Manufacturing process support spaces
- + Sterile storage spaces for materials and final product
- + Buffer and media prep rooms
- + Decontamination rooms with autoclaves
- + Office spaces
- + Central utility plant

A more definitive project scope, budget and schedule will be determined during the pre-construction phase and approved by the Board prior to construction contract award.

Other Major Fiscal Impacts:

None.

Agenda Item No. 7

**THE TEXAS A&M UNIVERSITY SYSTEM
FACILITIES PLANNING AND CONSTRUCTION**
Office of the Chief Financial Officer and Treasurer
September 21, 2012

Members, Board of Regents
The Texas A&M University System

Subject: Approval to Amend the FY 2013-FY 2017 Texas A&M University System Capital Plan to Add the Pandemic Influenza Facility Project (Project No. 1-3150) for The Texas A&M University System with a Fiscal Year 2013 Start Date

I recommend adoption of the following minute order:

“The request to amend the FY 2013-FY 2017 Texas A&M University System Capital Plan to add the Pandemic Influenza Facility Project for The Texas A&M University System with a FY 2013 start date and a total planning amount of \$78,431,373 is approved.

The amount of \$7,500,000 is appropriated from Account No.01-048560, Emerging Technology Fund-BARDA, for pre-construction services and related project costs, subject to finalization of state funding for the Center for Innovation in Advanced Development & Manufacturing.”

Respectfully submitted,

[ORIGINAL SIGNED BY]

Gregory R. Anderson
Chief Financial Officer and Treasurer

Approval Recommended:

[ORIGINAL SIGNED BY]

John Sharp
Chancellor

Approved for Legal Sufficiency:

[ORIGINAL SIGNED BY]

Ray Bonilla
General Counsel